No Data
Vistagen Expands Global Intellectual Property Portfolio With New Patents For PH80 Nasal Spray; Investigational Treatment For Migraine, Hot Flashes Due To Menopause, Premenstrual Dysphoric Disorder, And Dysmenorrhea
Express News | Vistagen Therapeutics Inc: All of New Patents Are Expected to Be in Effect Until 2040
Express News | Vistagen Broadens Ph80 Global Intellectual Property Portfolio With New Patents for the Treatment of Migraine
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q4 2024 Earnings Conference
No Data